• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Spruce Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/6/25 4:05:09 PM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SPRB alert in real time by email
    8-K
    0001683553false00016835532025-05-062025-05-06

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 6, 2025

     

     

    Spruce Biosciences, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

     

    Delaware

    001-39594

    81-2154263

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    611 Gateway Boulevard, Suite 740

     

    South San Francisco, California

     

    94080

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 415-655-4168

     

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.0001 per share

     

    SPRB

     

    *

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    * The registrant’s common stock began trading exclusively on the OTC Pink Marketplace on April 29, 2025 under the symbol “SPRB”.

     

     

     


     

    Item 2.02 Results of Operations and Financial Condition.

    On May 6, 2025, Spruce Biosciences, Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2025 and providing corporate updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

    All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

     

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

    Exhibit

    Number

     

    Description

     

     

     

    99.1

    Press Release of Spruce Biosciences, Inc., dated May 6, 2025

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    1


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

     

     

    SPRUCE BIOSCIENCES, INC.

     

     

     

     

    Date:

    May 6, 2025

    By:

    /s/ Samir Gharib

     

     

     

    Samir Gharib
    President and Chief Financial Officer

     

    2


    Get the next $SPRB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SPRB

    DatePrice TargetRatingAnalyst
    12/11/2024Mkt Outperform → Mkt Perform
    JMP Securities
    12/11/2024Outperform → Perform
    Oppenheimer
    3/14/2024Buy → Neutral
    Guggenheim
    3/14/2024$9.00 → $2.00Outperform → Market Perform
    Leerink Partners
    3/14/2024$9.00 → $2.00Outperform → Sector Perform
    RBC Capital Mkts
    3/14/2024Buy → Neutral
    Ladenburg Thalmann
    3/14/2024Buy → Neutral
    H.C. Wainwright
    2/21/2024$10.00Buy
    Guggenheim
    More analyst ratings

    $SPRB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Spruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market

      Relisting Contingent Upon Stockholder Approval of Reverse Stock Split Trading on Nasdaq Capital Market Anticipated to Commence On or Before August 5, 2025 Spruce Biosciences, Inc. (OTC:SPRB) ("Spruce"), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, announced that it has received approval from The Nasdaq Stock Market LLC ("Nasdaq") to resume trading of its common stock on the Nasdaq Capital Market subject to Spruce regaining compliance with Nasdaq's minimum bid price requirement on or before August 5, 2025. "We are pleased by Nasdaq's decision to lift its trading suspensio

      6/12/25 8:00:00 AM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

      Acquisition of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) Biologics License Application (BLA) Submission to U.S. FDA for TA-ERT Expected in 1H 2026 Spruce Biosciences, Inc. (OTC:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2025 and provided corporate updates. "With no FDA-approved treatments currently available to treat MPS IIIB, TA-ERT has the potential to be a groundbreaking advancement for patients and families impacted by t

      5/6/25 4:01:00 PM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

      Biologics License Application (BLA) Submission to U.S. FDA for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Anticipated in 1H 2026 Spruce to Host Conference Call Today at 8:30 a.m. ET Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the company's new corporate strategy and acquisition of tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). "This is truly a transformative moment for Spruce as we focus our expertise in rare disease on a potential near-te

      4/15/25 7:00:00 AM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Spruce Biosciences downgraded by JMP Securities

      JMP Securities downgraded Spruce Biosciences from Mkt Outperform to Mkt Perform

      12/11/24 8:25:53 AM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spruce Biosciences downgraded by Oppenheimer

      Oppenheimer downgraded Spruce Biosciences from Outperform to Perform

      12/11/24 8:25:37 AM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spruce Biosciences downgraded by Guggenheim

      Guggenheim downgraded Spruce Biosciences from Buy to Neutral

      3/14/24 8:20:07 AM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF MEDICAL OFFICER Charlton Ralph William Iii converted options into 164,750 shares and covered exercise/tax liability with 58,784 shares, increasing direct ownership by 191% to 161,339 units (SEC Form 4)

      4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)

      12/20/24 8:30:02 PM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT AND CFO Gharib Samir M. converted options into 229,750 shares and covered exercise/tax liability with 81,976 shares, increasing direct ownership by 73% to 350,550 units (SEC Form 4)

      4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)

      12/20/24 8:28:58 PM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF EXECUTIVE OFFICER Szwarcberg Javier B. converted options into 559,500 shares and covered exercise/tax liability with 199,630 shares, increasing direct ownership by 335% to 467,191 units (SEC Form 4)

      4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)

      12/20/24 8:28:11 PM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRB
    SEC Filings

    See more
    • Spruce Biosciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

      8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)

      6/12/25 8:10:45 AM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Spruce Biosciences Inc.

      DEFA14A - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)

      6/12/25 8:05:03 AM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Spruce Biosciences Inc.

      DEFA14A - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)

      6/6/25 4:10:04 PM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRB
    Leadership Updates

    Live Leadership Updates

    See more
    • Spruce Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

      Spruce Reports Interim Data from Phase 2 POWER Proof-of-Concept Study in Polycystic Ovary Syndrome (PCOS) CAHmelia Program in Adult Classic Congenital Adrenal Hyperplasia (CAH) Surpasses 75% Enrollment in CAHmelia-203 and Approaches 75% Enrollment in CAHmelia-204 Screening Underway for Cohort 3 in CAHptain Study for Pediatric Classic CAH Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2023 and provided corporate updates. "Our goal with the POWER study is to ass

      8/14/23 4:00:00 PM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spruce Biosciences Appoints Percival Barretto-Ko to Board of Directors

      Accomplished life sciences industry executive brings more than 20 years of commercial and biopharmaceutical expertise to Spruce Board Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced the appointment of Percival Barretto-Ko to the company's Board of Directors. Concurrently, Dina Chaya, Ph.D., has stepped down from the Board of Directors. "On behalf of Spruce, I am pleased to welcome Percival Barretto-Ko to our Board of Directors," said Mike Grey, Executive Chairman of Spruce Biosciences. "Percival is an accomplished and

      5/25/23 8:00:00 AM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spruce Biosciences Reports First Quarter 2023 Financial Results and Provides Corporate Updates

      CAHmelia Program in Adult Classic Congenital Adrenal Hyperplasia (CAH) Achieves 50% Enrollment in CAHmelia-204 and Approaches 75% Enrollment in CAHmelia-203 Enrollment in P.O.W.E.R. Study for Polycystic Ovary Syndrome (PCOS) Complete – Topline Results Anticipated in Q3 2023 Cohort 1 for Phase 2 CAHptain Study in Pediatric Classic CAH Fully Enrolled Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the quarter ended March 31, 2023 and provided corporate updates. "I am pleased by the meaningful pro

      5/15/23 8:00:00 AM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRB
    Financials

    Live finance-specific insights

    See more
    • Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

      Biologics License Application (BLA) Submission to U.S. FDA for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Anticipated in 1H 2026 Spruce to Host Conference Call Today at 8:30 a.m. ET Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the company's new corporate strategy and acquisition of tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). "This is truly a transformative moment for Spruce as we focus our expertise in rare disease on a potential near-te

      4/15/25 7:00:00 AM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

      CAHmelia-203 Study of Tildacerfont in Adult Classic Congenital Adrenal Hyperplasia (CAH) with Severe Hyperandrogenemia Did Not Meet Primary Efficacy Endpoint Positive Data from CAHptain-205 Study of Tildacerfont in Pediatric Classic CAH Supports Further Dose-Ranging Across Additional Dosing Cohorts Topline Results from CAHmelia-204 Study of Tildacerfont in Adult Classic CAH Evaluating Glucocorticoid (GC) Reduction Anticipated in Third Quarter of 2024 Resource Prioritization and Cost Reductions Extend Cash Runway Through End of 2025 Conference Call Today at 4:30 p.m. ET Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commerci

      3/13/24 4:08:00 PM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Spruce Biosciences Inc.

      SC 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)

      11/14/24 5:45:17 PM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Spruce Biosciences Inc.

      SC 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)

      11/14/24 4:39:47 PM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Spruce Biosciences Inc.

      SC 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)

      11/12/24 4:10:36 PM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care